ML 021
Alternative Names: ML-021Latest Information Update: 22 May 2024
At a glance
- Originator MapLight Therapeutics
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 30 Apr 2024 Preclinical trials in Parkinson's disease in USA (unspecified route), prior to April 2024 (Maplight therapeutics pipeline, April 2024)